Innovating in the Fight against Brain Tumors

Rare Cancer CGT

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

Tumor-Agnostic

Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology

David Alvaro, Ph.D.

Pharma's Almanac

Basket Trials

Basket Trials and the Future of Rare Cancer Research

David Alvaro, Ph.D.

Pharma's Almanac

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

Psych R&D

Rebuilding the Psychiatric Drug Discovery Pipeline

David Alvaro, Ph.D.

Pharma's Almanac

Ovarian Cancer

Oncolytic Viruses at a Turning Point: Advancing Olvi-Vec for Advanced Ovarian Cancer

David Alvaro, Ph.D.; Jason Litten, M.D.

Pharma's Almanac

Tariffs

The Intersection of Pharmaceutical Tariffs, Outsourcing, and Investment: Balance is Key

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Partnerships

What does a “true strategic partnership” between sponsors and CDMOs look like in today’s environment?

Pharma's Almanac

CMC and Investment

Where Capital Meets CMC: The Emerging Role of CDMOs in Investor Risk Assessment

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

R&D Funding

When Fewer Shots on Goal Change the Science: How Capital Discipline Is Reshaping R&D Strategy

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

Risk Sharing

Risk-Sharing Rewritten: How Biopharma Partnerships Are Redesigning Incentives Beyond the Deal

David Alvaro, Ph.D.

Pharma's Almanac